DOCSLIB.ORG

Post-Covid Management Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Post-Covid Management Protocol COVID-19 POST-COVID MANAGEMENT PROTOCOL July 21 CME INDIA CME 1 CME INDIA CME INDIA Post-COVID-19 Management Protocol First published: 16th August 2021. With the rapid rise in Covid-19 cases in INDIA, CME INDIA has now compiled its own guidelines with inputs from key medical experts. The goal of this document is to help the medical community in managing the current Covid-19 situation. This document will be updated from time to time, so please check www.cmeindia.in and CME INDIA Downloads section regularly. Alternatively, you can choose to navigate to the various key sections of CME INDIA: Explore CME INDIA Repository Examine CME INDIA Case Study Read History Today in Medicine Register for Future CMEs View CME INDIA Downloads 2 CME INDIA Basic Framework By: Dr. Nishith Kumar, MD, FAPSR, Consultant Department of Pulmonary Medicine, OMC, Ranchi. Dr. Akash Kumar Singh, Internist and Diabetologist, Spandan Multi-Specialty Hospital, Vadodara. Dr. Sankararaman N, DM Pulmonary Medicine Fellow at Vallabhbhai Patel Chest Institute, New Delhi. Edited By: Dr. N.K. Singh, MD, FICP, Diabetologist Physician, Dhanbad, Editor - cmeindia.in. Advisor and Reviewer: Dr. Shashank R Joshi, MD, DM, FICP, FACP(USA), FACE(USA), FRCP (Lon, Glsg & Edin) (Padma Shri Awardee 2014). Chair, International Diabetes Federation Southeast Asia, Past Dean, Indian College of Physicians. Member, Covid 19 State Task Force, Maharashtra. Invitee Reviewer Dr. Banshi Saboo, National President, RSSDI, Ahmedabad. Dr. Mangesh Tiwaskar, Consultant Physician & Diabetologist, Mumbai, Hon. General Secretary, API. Invitee Editor Dr. S. K. Gupta, MBBS MD (Med), CFM (France), Senior Consultant Physician, Max Hospital, Delhi. Reviewer Dr. Amita Nene, MD, DETRD, FCCP, Head - Dept. of Pulmonary Medicine, Bombay Hospital & Medical Research Centre, Mumbai. Dr. Chandrakant Tarke, MD, DNB, DM, MNAMS, EDRM, Pulmonologist, Apollo Hospital, Hyderabad. Dr. Murali Mohan BV, Pulmonologist, Narayana Medical Centre, Bengaluru. Inputs: Dr. Anil Kumar Virmani, MD, DRM, FICP, FIACM, FACP, FDI, Consultant Physician and Cardio-Diabetologist, Jamshedpur, Jharkhand. 3 CME INDIA Prof (Dr.) Aravinda J, MD, MRCP (London), Triple FRCP (Edinburgh, London, Glasgow) Chairman & Chief Diabetologist, Dr. Aravind's Diabetes Center, Basaveshwarnagar Bengaluru. Dr. Arvind Gupta, MD, FRCP (Glasgow), FRCP (Edin), FICP, FACE, Senior Consultant and Head, Department of Diabetes, Obesity and Metabolic Disorders, Rajasthan Hospital, Opposite, Jaipuria Govt Hospital, Jaipur-302018 Dr. Brij Mohan, Kanpur, MD, FICP, FICAM, Fellow Diabetes India, Consultant Diabetologist Physician, Kanpur. Dr. Prof Deepak Kumar Jumani, Senior Sexual Health physician and counselor, Asst. prof of medicine Sir JJ group of Govt Hospitals & Govt medical college, Mumbai. Dr. Meena Chhabra, Senior visiting consultant and diabetes specialist sir Gangaram hospital, Delhi. Dr. Sanjeev R. Pathak, Diabetologist, Ahmedabad. Dr. Noni G Singha, MD, FICP, Consultant Physician, Dibrugarh, Assam. Dr. Prabhat Agrawal MD (gold medalist) P g diploma of diabetes (London) MAMS, FRCP, FICP, FACP, FIACM, Professor of medicine, S N Medical college, Agra. Dr. Basab Ghosh, Sr Diabetologist, Agartala, Tripura. Dr. Th. Premchand Singh, MD, FCCP, Commonwealth Medical Fellow, UK. Retired Professor of Medicine, Regional Institute of Medical Sciences, Imphal. Dr. Bijay Patni, Diabetologist & Physician, Kolkata. Dr. Somnath, Medical Director & Chief of Medicine Diabetes Critical care, Tricolour Hospital, Hyderabad. Dr. B. Harish Darla, MD, DNB, MRCP(Endocrinology), MRCP(Medicine), FRCP (Edinburgh & Glasgow), Consultant Physician in Diabetes & Endocrinology, Director: Darla's Health Care, Mysore. Dr. Amit Kumar, M.D. (Derm. & STD), Cosmo, Ranchi. Dr. Vaibhav Agnihotri, (DCH, DNB (Paediatrics), Fellowship Neonatology (IAP), PGPN, Boston, PCBD USA), Jaipur. Dr. Richa Agnihotri, MBBS, DGO, DNB (Obs & Gynae), FGES (lap surgeon), Jaipur. Special Thanks to Dr. Suresh Kumar, Infectious disease specialist, Apollo Hospital, Chennai. Special Thanks to Dr. B. B Rewari, MD, FRCP, Former Asso. Prof. of Medicine, Dr. RML Hospital, New Delhi. Scientist HIV/AIDS/STI/Hepatitis at WHO SEARO. Design and Content Management: Mr. Rishav Manaswi, Founder (Dynamic Cognition), MBA (France), [email protected] 4 CME INDIA Disclaimer This is the first-ever guideline by CME INDIA on Post-COVID-19 Management. It has been framed and reviewed by experts. As there are lots of guidelines and not all agree on the same protocol, physicians are advised to apply their own wisdom especially as recommendations keep changing. Document Flow (Best viewed using Google/Drive pdf viewer. Use below links to go to a specific part.) Introduction (1,2) ................................................................................................................... 7 Timeline of Acute Covid-19 And Post-Acute Covid-19 Phases (1,3,4) ........................................ 8 Epidemiology (3,5) ............................................................................................................... 10 Mechanisms Involved in Post-Acute Covid-19 Syndrome (6) ................................................. 12 Common Lingering Symptoms of Post-Acute Covid-19 Syndrome (7-13) ................................ 13 Post-Covid-19 Symptoms by Organ System ........................................................................... 14 Timing of Follow Up (14-18) .................................................................................................. 18 Assessment (19-20) .............................................................................................................. 19 General Laboratory Testing (19-20)....................................................................................... 20 Cardiopulmonary Assessment (21) ....................................................................................... 21 Chest Imaging (16,22-24) ...................................................................................................... 21 Timing of Chest Imaging (25) ................................................................................................ 22 Cardiac Testing (26) .............................................................................................................. 23 Pulmonary Function Test (16,27,28)...................................................................................... 23 Evaluating Exercise Capacity and Oxygenation (26) ............................................................... 24 Six-Minute Walk Test Technique (29-31) ............................................................................... 24 Alternative To 6 MWT (32) ................................................................................................... 25 Management of Dyspnea ..................................................................................................... 25 Breathing Control (32) .......................................................................................................... 26 Breathing Techniques (32) .................................................................................................... 26 5 CME INDIA Management of Cough (26) .................................................................................................. 27 Management of Chest Discomfort/Tightness/Pain ................................................................ 27 Management of Orthostasis (34) .......................................................................................... 29 Management of Hypercoagulability/Thrombosis .................................................................. 29 Management of Olfactory/Gustatory Symptoms (35-39)....................................................... 30 Management of Fatigue (40) ................................................................................................ 31 Management of Lung Fibrosis (61) ........................................................................................ 31 Rehabilitation (28,41-42) ...................................................................................................... 32 Yoga Practices for Prevention, Rehabilitation, and To Increase Immunity (43-51) .................. 33 Long Haul Syndrome in Children (54-56) ............................................................................... 35 Post-Covid Pregnancy Related Pearls (58,59,60) .................................................................... 39 Post-Covid-19 Diabetes (61-62) ............................................................................................. 40 Post-Covid Dermatological Manifestations ........................................................................... 41 Post-Covid Sexual Issues (67) ................................................................................................ 42 Suggested Useful Link ........................................................................................................... 44 References ........................................................................................................................... 46 6 CME INDIA Introduction (1,2) The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen which has resulted in both global healthcare crises and strained health resources. The pandemic has also caused morbidity and mortality at an unprecedented scale globally. COVID-19 is now recognized to affect multi-organs
Load more

Recommended publications
  • Sepsivac to Be Tested for Covid-19
    Sepsivac to be Tested for Covid-19 drishtiias.com/printpdf/sepsivac-to-be-tested-for-covid-19 Why in News The Council of Scientific and Industrial Research (CSIR) has decided to test its new drug against Sepsis, named Sepsivac to treat critical patients of Covid-19. The drug will be tested in 50 Covid-19 patients at the All-India Institute of Medical Sciences in Delhi and Bhopal, and Post Graduate Institute of Medical Education and Research, Chandigarh. Key Points New Drug Against Sepsis The new drug has recently been approved for marketing in India and would be available commercially as Sepsivac® from Ahmedabad-based Cadila Pharmaceuticals Limited. The pharmaceutical company was supported by CSIR laboratories led by Indian Institute of Integrative Medicine (IIIM), Jammu in development of this drug, which has also been found effective for leprosy patients. 1/3 Gram Negative Sepsis and Covid-19 Sepsis is a serious life-threatening condition caused when the body's response to any kind of infection goes out of balance, triggering changes that can lead to multi-organ failure. Gram negative bacteremia (presence of bacteria in the bloodstream) in the critically ill patient is synonymous with gram negative sepsis. Gram-negative bacteria have built-in abilities to find new ways to be resistant and can pass along genetic materials that allow other bacteria to become drug-resistant as well. According to scientists, there are some clinical similarities between patients suffering from gram-negative Sepsis and Covid-19. A Covid-19 infection leads to a cytokine storm, quite similar to the one seen in Sepsis, when there is a heightened immune response and over production of immune cells because of which the body starts attacking its own cells.
    [Show full text]
  • Abstracts Criticare – Ijccm2021
    ABSTRACTS CRITICARE – IJCCM2021 1. Acute Kidney Injury and Hemofiltration being 51.97 ± 10.52. Nephrotic level proteinuria (4+) is significantly high (22.2%) in Group1 patients as compared to the rest. Group 3 predominantly (34.3%) shows insignificant proteinuria which is less 1. Acute Kidney Injury in Severely Preeclamptic Patients Admitted than 250 mg/day. 3+ proteinuria is most common. Discussions: to ICU: Epidemiology and Role of Serum Neutrophil Gelatinase- NDKD amounted to 52.87% [out of which NDKD superimposed on Associated Lipocalcin. (Conference Abstract ID: 176) diabetic kidney disease (DKD) was 30%, isolated NDKD was 22.87%]. Pooja Yadav, Asha Tyagi, Asha Tyagi, Rashmi Salhotra, Shukla The pro-portion of NDKDs ranged from 21 to 52% in other studies. Das, Praveen Singh Conclusion: NDKDs do occupy a considerable fraction of kidney UCMS and GTB Hospital, Delhi, India diseases of type 2 diabetes patients. Their presentation is however DOI: 10.5005/jp-journals-10071-23711.1 different (low degrees of proteinuria, younger patient age). Introduction: Critically ill preeclamptic patients may have risk factors for acute kidney injury (AKI). Neutrophil gelatinase- 3. Failing Kidney and a Preserved Heart. (Conference Abstract associated lipocalcin (NGAL) is a validated biomarker to predict ID: 92) AKI. We could locate scanty data regarding the epidemiology of C Jayadevi AKI and the role of NGAL in preeclamptic patients admitted to Govt Villupuram Medical College Hospital, Villupuram, Tamil Nadu, ICU. Materials and methods: Preeclamptic patients admitted to India multidisciplinary ICU were included. The occurrence of AKI and its DOI: 10.5005/jp-journals-10071-23711.3 severity for the entire ICU stay using KDIGO criteria, risk factors, and serum NGAL were assessed.
    [Show full text]
  • June 2020, Issue 4
    All iNDIA INSTITUTE OF MEDICAL SCIENCES, MANGAlagiri (AP) A Pharmacology bulletin MAy-JUne 2020, Issue 4 FROM THE EDITORIAL DESK…. Welcome to the Fourth Issue of ‘ESSENCE’ from AIIMS Mangalagiri, We are in the midst of the COVID 19 pandemic which has now affected more than 4 million people with approx 2.5 lakhs deaths till date. With increasing cases and fatalities there is a sense of urgency to identify drugs both old and new that may have beneficial effects on the disease morbidity and mortality. The current issue highlights the various issues involving the use of drugs that have been employed so far in the fight against COVID 19. Disasters and pandemics like COVID 19 pose unique challenges to providing health care. In the scenarios of pandemics and disasters, sessions of telemedicine can reduce the risks to both health care workers and patients, and thus prevent the transmission of infectious diseases. Institutions invested in telemedicine help to increase the available human resource and allocate them at the respective hospitals to provide physical care for patients in the time of crisis like this. With Covid-19 cases spreading across the country, India formally recognised the practice of telemedicine recently. The government’s new “telemedicine practice guidelines” legitimise the practice of remote consultations. The current issue discusses the guidelines pertaining to prescribing medications as per these new telemedicine guidelines. Further, like always, the current issue also discusses the recent drug approvals and also safety alerts of various drugs. Finally, the readers can test their pharmacology knowledge with the cross word puzzle on ‘Drugs causing Hyperkalemia ’.
    [Show full text]
  • Review of Current Clinical Management Guidelines for COVID-19 with Special Reference to India
    Drug Discoveries & Therapeutics. 2020; 14(4):171-176. 171 Review DOI: 10.5582/ddt.2020.03059 Review of current clinical management guidelines for COVID-19 with special reference to India Rohit Kumar1, Kutty Sharada Vinod2, Ankit Mittal1, Shreya Das Adhikari3, Nitin Gupta4,* 1 Department of Medicine, All India Institute of Medical Sciences, New Delhi, India; 2 Department of Pulmonary Medicine, All India Institute of Medical Sciences, New Delhi, India; 3 Departments of Oncoanaesthesia and Palliative Medicine, Dr Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India; 4 Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. SUMMARY The healthcare sector has been overwhelmed by the global rise in the number of COVID-19 cases. The primary care physicians at the forefront of this pandemic are being provided with multiple guidelines (state, national, international). The aim of this review was to examine the existing guidelines for congruence and critically analyze them in light of current evidence. A discordance was noted between the national and state guidelines with respect to indication, duration and dosage of antivirals, steroids/immunomodulators, anticoagulation and convalescent plasma. The lack of concordance between various guidelines mandates the need for a unified national guideline that is regularly updated. Keywords Coronavirus disease 19, hydroxychloroquine, remdesivir, dexamethasone, tocilizumab, convalescent plasma 1. Introduction The guidelines from the following states were available- Kerala (5), Karnataka, Maharashtra and West Bengal The current coronavirus disease 2019 (COVID-19) (6). These guidelines were reviewed independently pandemic has put a challenging situation in front of by three reviewers.
    [Show full text]